INTeRAcT: Intensive Motor Rehabilitation With Technology for Patients With Central Neurological Disease

Sponsor
KU Leuven (Other)
Overall Status
Recruiting
CT.gov ID
NCT05970367
Collaborator
AZ Herentals (Other), Vrije Universiteit Brussel (Other)
100
2
2
28.7
50
1.7

Study Details

Study Description

Brief Summary

This project will consist of 1 large clinical trial with 2 core concepts: (1) Clinical benefits of an intensive rehabilitation programme using advanced technology, compared to the control group; (2) A full health economic evaluation combined with model-based estimation of costs and benefits.

Condition or Disease Intervention/Treatment Phase
  • Other: Intensive rehabilitation programme
Phase 2/Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomised controlled trial (RCT)Randomised controlled trial (RCT)
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Impact of an Intensive Motor Rehabilitation Programme Integrating Technology for Adults With Central Neurological Disease: A Randomised Controlled Rehabilitation Study in the Chronic Phase
Actual Study Start Date :
Jul 10, 2023
Anticipated Primary Completion Date :
Dec 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intensive rehabilitation program

3 weeks of intensive rehabilitation --> follow-up 9 months standard care

Other: Intensive rehabilitation programme
Intensive rehabilitation using advanced technology, based on the patient's goals. Including cardiovascular fitness training, goal-oriented training, physiotherapy with and without advanced technology and self-management.

No Intervention: Standard care

Follow-up 9 months standard care --> 3 weeks of intensive rehabilitation

Outcome Measures

Primary Outcome Measures

  1. Change in Functional Independence Measure (FIM) [Baseline - 3weeks - 9months]

    The Functional Independence Measure (FIM), which measures independence in daily functioning after stroke. The FIM consists of 18 items designed to assess to what extent a person needs assistance in performing activities of daily living safely and efficiently. The activities consist of a number of basic skills related to self-care, pelvic floor function, transfers, gait, communication and social abilities. The FIM has acceptable reliability and has been found valid in people with stroke. Min: 13; Max: 91; Higher = better

  2. Change in Spinal Cord Independence Measure (SCIM) [Baseline - 3weeks - 9months]

    Spinal Cord Independence Measure (SCIM), an assessment of achievements of daily function of patients with spinal cord lesions. The scale consists of 19 tasks organized in 3 subscales: self-care, respiration and sphincter management, and mobility. The SCIM is valid and reliable. Min: 0; Max: 100; Higher = better

Secondary Outcome Measures

  1. Change in The Canadian Occupational Performance Measure (COPM) [Baseline - 3weeks - 9months]

    The Canadian Occupational Performance Measure (COPM), is an evidence-based outcome measure designed to capture a patient's self-perception of performance in everyday living, over time. This outcome can be used in both study populations. Min: 1; Max: 10; Higher = better

  2. Change in EQ-5D-5L [Baseline - 3weeks - every month during follow-up - 9 months]

    EQ-5D-5L, measures quality of life at five levels of health (mobility, self-care, daily activities, pain/discomfort and anxiety/depression). From this, a weighted health index can be calculated for an individual or population. This scale can also be used for both populations. Min: 1; Max: 100; Higher = better

  3. Change in Goal Attainment Scaling (GAS) [Baseline - 3weeks - 9months]

    Goal Attainment Scaling (GAS), is an individualised evaluation method. It is scored on an ordinal 5-point scale, which captures a person's individual treatment goal and is scored afterwards on the achievement of that treatment goal. The GAS can and will be used for both stroke and spinal cord injury. Min: -2; Max: +2; Higher = better

  4. Change in The fatigue severity scale (FSS) [Baseline - 3weeks - 9months]

    The fatigue severity scale (FSS) contains 9 questions assessing the perceived severity of fatigue symptoms in the past week in various daily situations. The patient indicates the extent to which fatigue determines functioning. Again, this will be used for both stroke and spinal cord injury. Min: 9; Max: 63; Higher = worse

  5. Borg Rating of Perceived Exertion Scale [During intervention (up to 9 months)]

    During the intervention the Borg Rating of Perceived Exertion Scale will be completed to after every therapy block to assess subjective experiences of the patients during physical load. Min: 6; Max: 20; Higher = worse

  6. Change in the 6-minute Walk-Test (6MWT) [Baseline - 3weeks - 9months (stroke only)]

    The 6-minute Walk-Test (6MWT) is used to measure functional capacity. The maximum distance the patient can cover within 6 minutes is measured.

  7. Change in the action research Arm Test (ARAT) [Baseline - 3weeks - 9months (stroke only)]

    The action research Arm Test (ARAT) is an observational measure to assess upper extremity performance (coordination, dexterity and functioning), including 19 items. Task performance is rated on a 4-point scale, ranging from 0 (no movement) to 3 (movement performed normally). Min: 0; Max: 57; Higher = better

  8. Change in rhe Fugl-Meyer Assessment (FMA) [Baseline - 3weeks - 9months (stroke only)]

    The Fugl-Meyer Assessment (FMA) is designed to assess motor functioning in upper and lower limbs, in patients with post-stroke. Patients are assessed on 50 test items and on an ordinal 3-point scale. Min: 0; Max: 100; Higher = better

  9. Change in the functional Ambulation Classification (FAC) [Baseline - 3weeks - 9months (stroke only)]

    The functional Ambulation Classification (FAC): is a functional walking test that evaluates ambulation ability. This 6-point scale assesses ambulation status by determining how much human support the patient needs when walking, whether or not they use a personal assistive device. Min: 0; Max: 5; Higher = better

  10. Change in the 10 Meter Walk Test (10MWT) [Baseline - 3weeks - 9months (stroke only)]

    The 10 Meter Walk Test (10MWT) measures the time needed for a person to walk 10 meters. It is used to determine functional mobility and gait.

  11. Change in the Stroke Self-efficacy Questionnaire [Baseline - 3weeks - 9months (stroke only)]

    The Stroke Self-efficacy Questionnaire Evaluate individuals' confidence in carrying out activities of daily living. Min: 0; Max: 60; Higher = better

Other Outcome Measures

  1. Change in health economic evaluation [Baseline - 3weeks - every month during follow-up - 9 months]

    Through this questionnaire, health economic data are surveyed to estimate direct and indirect costs that participants have due to their condition. The following types of resource use will be collected: primary care, emergency visits, inpatient stays, outpatient services, medication, transport costs, the estimation of the amount of informal care, days away from work, and social benefits (e.g. sickness leave payments).

  2. Therapy diary [every month during follow-up (up to 9 months)]

    Using a therapy diary that the investigators ask patients to fill in every time they have been to the physical therapist/psychologist. On a monthly basis, these records are requested via mail.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures;

  2. A diagnosis of central neurological disease, made by a specialist. Conditions may include stroke or spinal cord injury:

  3. Stroke: Participants must have received a diagnosis of stroke for the first time, have been diagnosed at least 3 months ago, and live at home.

  4. SCI: Participants have a rating A, B, C or D on the American Spinal Injury Association (ASIA) measurement scale, which refers to patients with complete or incomplete impairment. All levels of SCI can be included, if there is a clear patient need linked to the upper and/or lower extremities.

  5. At least 3 months post discharge from hospital/rehabilitation centre, living at home;

  6. Having a maximum recovery of 85% of independence in daily functioning (FIM/SCIM);

  7. Had a normal functional state prior to the pathology: a pre-pathology Barthel Index > 85/100;

  8. Unilateral or bilateral weakness of the affected upper or lower limbs (No maximum score in all affected limbs = motricity index: score 5 on 3/3 segments)

  9. Having the clinical opportunity to engage in exercise therapy with available technology, assessed by a specialist;

  10. Age of > 18 years;

  11. Sufficient cognitive ability to understand the games and give informed consent, assessed by a specialist;.

Exclusion Criteria:
  1. Having other neurological or musculoskeletal conditions that may affect the protocol, assessed by a specialist;

  2. No ability to initiate movements against gravity in the upper and lower limbs;

  3. Severe visual impairment, communication, cognitive and language formation problems that would prevent the intervention and measurement process, assessed by a specialist;

  4. Any disorder, which in the investigator's opinion might the compromise participant's safety or compliance with the CIP;

  5. Female who is pregnant, breast-feeding.

Contacts and Locations

Locations

Site City State Country Postal Code
1 AZ Herentals Herentals Belgium 2200
2 KU Leuven Leuven Belgium 3000

Sponsors and Collaborators

  • KU Leuven
  • AZ Herentals
  • Vrije Universiteit Brussel

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Prof Geert Verheyden, Prof., KU Leuven
ClinicalTrials.gov Identifier:
NCT05970367
Other Study ID Numbers:
  • S67164
First Posted:
Aug 1, 2023
Last Update Posted:
Aug 1, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Prof Geert Verheyden, Prof., KU Leuven
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 1, 2023